Huntington's Disease Trial, Recruiting NCT05360082 Sponsor: Universitaire Ziekenhuizen KU Leuven Condition: Huntington's Disease
Back to Huntingtons Disease

Huntington's Disease Trial, Recruiting

NCT05360082
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

This trial is looking for three different groups of participants:

Group 1 – Healthy volunteers (10–20 people):

  • You are considered to be in good general health based on a doctor's review of your medical history, physical exam, blood tests, and urine tests
  • You have no history or current signs of any major brain, nervous system, or mental health condition
  • If you are under 60, your brain MRI scan shows no significant abnormalities; if you are 60 or older, only a small, acceptable level of age-related white matter changes on your brain scan is allowed (confirm with trial site)

Group 2 – People with Huntington's disease (HD) at Stage 3 (10 people):

  • You carry a specific gene change (CAG repeat expansion between 40 and 50) linked to Huntington's disease
  • You are classified as Stage 3 according to a specific HD staging system (confirm with trial site)
  • You score 10 or above on a standard Huntington's disease functional assessment scale (confirm with trial site)

Group 3 – People with Huntington's disease (HD) at Stage 2 (10 people):

  • You carry a specific gene change (CAG repeat expansion between 40 and 50) linked to Huntington's disease
  • You are classified as Stage 2 according to a specific HD staging system (confirm with trial site)
  • You fall within a specific range on a Huntington's disease progression score (confirm with trial site)

Who may not be able to join:

  • You have a mental health or neurological condition — for Huntington's disease participants, any condition other than HD itself
  • You have a serious ongoing medical illness affecting major organs or body systems
  • Your brain scan shows a significant level of white matter changes or other notable abnormalities
  • You currently drink more than 15 units of alcohol per week, have a history of alcohol misuse, or currently use recreational drugs
  • You have a medical reason why you cannot have an MRI scan (for example, a metal implant)
  • You experience claustrophobia (fear of enclosed spaces) or are unable to lie still for at least 30 minutes inside a scanner
  • You are unwilling to avoid intense or unusual physical exercise (such as weightlifting, running, or cycling) from your pre-study visit through to the end of the scan
  • You (or your guardian, if applicable) do not fully understand what the study involves
  • You (or your guardian) are unwilling or unable to complete all study procedures, or the lead researcher has any other concern about your suitability
  • You are currently taking blood-thinning medication (anticoagulants)
  • You are currently pregnant or breastfeeding
  • You are a woman who could become pregnant and are unwilling to use appropriate contraception during the study and for at least 6 months after it ends
  • You are a man whose partner could become pregnant, and you are unwilling to use a condom until 90 days after the study ends (your partner should also use an effective form of contraception)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Koen Van Laere, MD, PhD, DSc, UZ/KU Leuven

Phone: +3216343714

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
18 November 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Compare Vt of [11C]UCB-J and [18F]SynVest-1 in manifest HD and healthy controls

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov